MeSH Review:
Cataplexy
Black,
Silber,
Krahn,
Fredrickson,
Pankratz,
Avula,
Walker,
Slocumb,
Lagrange,
Blaivas,
Gomez-Hassan,
Malow,
Arnulf,
Konofal,
Gibson,
Rabier,
Beauvais,
Derenne,
Philippe,
Dauvilliers,
Montplaisir,
Molinari,
Carlander,
Ondze,
Besset,
Billiard,
Lemon,
Strain,
Farver,
Mitler,
Hayduk,
Fronczek,
Lammers,
Balesar,
Unmehopa,
Swaab,
- Carbamazepine as a treatment for cataplexy. Vaughn, B.V., D'Cruz, O.F. Sleep. (1996)
- Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Anic-Labat, S., Guilleminault, C., Kraemer, H.C., Meehan, J., Arrigoni, J., Mignot, E. Sleep. (1999)
- Rasmussen's syndrome and new-onset narcolepsy, cataplexy, and epilepsy in an adult. Lagrange, A.H., Blaivas, M., Gomez-Hassan, D., Malow, B.A. Epilepsy & behavior : E&B. (2003)
- Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. John, J., Wu, M.F., Boehmer, L.N., Siegel, J.M. Neuron (2004)
- Treatment of narcolepsy with L-tyrosine: double-blind placebo-controlled trial. Elwes, R.D., Crewes, H., Chesterman, L.P., Summers, B., Jenner, P., Binnie, C.D., Parkes, J.D. Lancet (1989)
- Prostaglandin E2 and its methyl ester reduce cataplexy in canine narcolepsy. Nishino, S., Mignot, E., Fruhstorfer, B., Dement, W.C., Hayaishi, O. Proc. Natl. Acad. Sci. U.S.A. (1989)
- Effect of genetically caused excess of brain gamma-hydroxybutyric acid and GABA on sleep. Arnulf, I., Konofal, E., Gibson, K.M., Rabier, D., Beauvais, P., Derenne, J.P., Philippe, A. Sleep. (2005)
- Effects of lateral hypothalamic lesion with the neurotoxin hypocretin-2-saporin on sleep in Long-Evans rats. Gerashchenko, D., Blanco-Centurion, C., Greco, M.A., Shiromani, P.J. Neuroscience (2003)
- Role of central alpha-1 adrenoceptors in canine narcolepsy. Mignot, E., Guilleminault, C., Bowersox, S., Rappaport, A., Dement, W.C. J. Clin. Invest. (1988)
- Clomipramine and clonazepam in cataplexy. Parkes, J.D., Schachter, M. Lancet (1979)
- Pharmacological aspects of human and canine narcolepsy. Nishino, S., Mignot, E. Prog. Neurobiol. (1997)
- Monoaminergic mechanisms and experimental cataplexy. Foutz, A.S., Delashaw, J.B., Guilleminault, C., Dement, W.C. Ann. Neurol. (1981)
- Dopamine D2 mechanisms in canine narcolepsy. Nishino, S., Arrigoni, J., Valtier, D., Miller, J.D., Guilleminault, C., Dement, W.C., Mignot, E. J. Neurosci. (1991)
- Sodium oxybate for cataplexy. Lemon, M.D., Strain, J.D., Farver, D.K. The Annals of pharmacotherapy. (2006)
- The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome. Fronczek, R., Lammers, G.J., Balesar, R., Unmehopa, U.A., Swaab, D.F. J. Clin. Endocrinol. Metab. (2005)
- Cholinergic mechanisms in canine narcolepsy--II. Acetylcholine release in the pontine reticular formation is enhanced during cataplexy. Reid, M.S., Siegel, J.M., Dement, W.C., Mignot, E. Neuroscience (1994)
- Locus coeruleus neurons: cessation of activity during cataplexy. Wu, M.F., Gulyani, S.A., Yau, E., Mignot, E., Phan, B., Siegel, J.M. Neuroscience (1999)
- Cataplexy-related neurons in the amygdala of the narcoleptic dog. Gulyani, S., Wu, M.F., Nienhuis, R., John, J., Siegel, J.M. Neuroscience (2002)
- Dopamine D3 agonists into the substantia nigra aggravate cataplexy but do not modify sleep [corrected]. Honda, K., Riehl, J., Mignot, E., Nishino, S. Neuroreport (1999)
- Cataplexy and monoamine oxidase deficiency in Norrie disease. Vossler, D.G., Wyler, A.R., Wilkus, R.J., Gardner-Walker, G., Vlcek, B.W. Neurology (1996)
- The roles of midbrain and diencephalic dopamine cell groups in the regulation of cataplexy in narcoleptic Dobermans. Okura, M., Fujiki, N., Kita, I., Honda, K., Yoshida, Y., Mignot, E., Nishino, S. Neurobiol. Dis. (2004)
- Hyperekplexia: a syndrome of pathological startle responses. Sáenz-Lope, E., Herranz-Tanarro, F.J., Masdeu, J.C., Chacón Peña, J.R. Ann. Neurol. (1984)
- Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. Nishino, S., Arrigoni, J., Shelton, J., Kanbayashi, T., Dement, W.C., Mignot, E. J. Neurosci. (1997)
- Age at onset of narcolepsy in two large populations of patients in France and Quebec. Dauvilliers, Y., Montplaisir, J., Molinari, N., Carlander, B., Ondze, B., Besset, A., Billiard, M. Neurology (2001)
- Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors. Reid, M.S., Tafti, M., Nishino, S., Siegel, J.M., Dement, W.C., Mignot, E. Sleep. (1994)
- Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Riehl, J., Honda, K., Kwan, M., Hong, J., Mignot, E., Nishino, S. Neuropsychopharmacology (2000)
- Analysis of hypocretin (orexin) antibodies in patients with narcolepsy. Black, J.L., Silber, M.H., Krahn, L.E., Fredrickson, P.A., Pankratz, V.S., Avula, R., Walker, D.L., Slocumb, N.L. Sleep. (2005)
- Benefits and risks of pharmacotherapy for narcolepsy. Mitler, M.M., Hayduk, R. Drug safety : an international journal of medical toxicology and drug experience. (2002)
- Novel chromosomal abberation in a patient with a unique sleep disorder. Hasegawa, Y., Morishita, M., Suzumura, A. J. Neurol. Neurosurg. Psychiatr. (1998)